HO
Therapeutic Areas
Tiantan Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Human Albumin | Hypovolemia, Burns, Hypoalbuminemia | Approved |
| Human Immunoglobulin (IVIG) | Primary Immunodeficiency, Autoimmune Diseases | Approved |
| Hepatitis B Immunoglobulin (HBIG) | Prevention of Hepatitis B | Approved |
| Tetanus Immunoglobulin | Prophylaxis/Treatment of Tetanus | Approved |
| Rabies Immunoglobulin | Post-exposure Prophylaxis for Rabies | Approved |
| Factor VIII | Hemophilia A | Approved |
| Prothrombin Complex Concentrate (PCC) | Bleeding in Hemophilia B | Approved |
| Inactivated Hepatitis A Vaccine | Prevention of Hepatitis A | Approved |
Leadership Team at Tiantan Bio
RO
Representative of CNBG/Sinopharm
Chairman of the Board
SI
Senior Industry Executive
General Manager / Chief Executive Officer (CEO)
FE
Financial Executive
Chief Financial Officer (CFO)
HO
Head of Plasma Division
Vice President, Plasma Products
HO
Head of Vaccine Division
Vice President, Vaccines
HO
Head of Research
Vice President, R&D
HO
Head of Quality
Vice President, Quality Control
HO
Head of Commercial
Vice President, Sales and Marketing
ID
Independent Director
Independent Non-Executive Director